Identifying prognostic features by bottom-up approach and correlating to drug repositioning

PLoS ONE

Volumn 10, Issue 3, 2015, Pages

  Li, Wei ^a,b,c   Yu, Jian ^b   Lian, Baofeng ^b,d   Sun, Han ^b,e   Li, Jing ^a,b,c   Zhang, Menghuan ^b,d   Li, Ling ^b   Li, Yixue ^b,d,e   Liu, Qian ^a,c   Xie, Lu ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b SHANGHAI CENTER FOR BIOINFORMATION TECHNOLOGY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d SHANGHAI JIAO TONG UNIVERSITY   (China)

^e INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANALYTIC METHOD; ARTICLE; BOTTOM UP METHOD; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; DRUG REPOSITIONING; FEMALE; GENE CLUSTER; GENE EXPRESSION; GENETIC CORRELATION; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN PROTEIN INTERACTION; RECURRENCE FREE SURVIVAL; SEX DIFFERENCE; SURVIVAL TIME; BIOLOGY; CARCINOMA, HEPATOCELLULAR; CLUSTER ANALYSIS; COHORT ANALYSIS; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; GENETICS; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; PROCEDURES; PROGNOSIS; SURVIVAL ANALYSIS;

TUMOR MARKER;

BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CLUSTER ANALYSIS; COHORT STUDIES; COMPUTATIONAL BIOLOGY; DRUG REPOSITIONING; FEMALE; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN INTERACTION MAPS; SURVIVAL ANALYSIS;

EID: 84928978619     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0118672     Document Type: Article

References (57)

1. El-Serag HB (2011) Hepatocellular carcinoma. N Engl J Med 365: 1118-1127. doi: 10.1056/NEJMra1001683 PMID: 21992124
2. European Association For The Study Of The L, European Organisation For R, Treatment Of C (2012) EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56: 908-943. doi: 10.1016/j.jhep.2011.12.001 PMID: 22424438
3. Kudo M, Chung H, Osaki Y (2003) Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 38: 207-215. PMID: 12673442
4. Leung TW, Tang AM, Zee B, Lau WY, Lai PB, et al. (2002) Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 94: 1760-1769. PMID: 11920539
5. Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19: 329-338. PMID: 10518312
6. (1998) A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 28: 751-755. PMID: 9731568
7. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56: 918-928. PMID: 2990661
8. Lagarde P, Perot G, Kauffmann A, Brulard C, Dapremont V, et al. (2012) Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. Clin Cancer Res 18: 826-838. doi: 10.1158/1078-0432.CCR-11-1610 PMID: 22167411
9. Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang DY, et al. (2008) Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 359: 1995-2004. doi: 10.1056/NEJMoa0804525 PMID: 18923165
10. Carter SL, Eklund AC, Kohane IS, Harris LN, Szallasi Z (2006) A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet 38: 1043-1048. PMID: 16921376
11. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536. PMID: 11823860
12. Nault JC, De Reynies A, Villanueva A, Calderaro J, Rebouissou S, et al. (2013) A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology 145: 176-187. doi: 10.1053/j.gastro.2013.03.051 PMID: 23567350
13. Kim SM, Leem SH, Chu IS, Park YY, Kim SC, et al. (2012) Sixty-five gene-based risk score classifier predicts overall survival in hepatocellular carcinoma. Hepatology 55: 1443-1452. doi: 10.1002/hep.24813 PMID: 22105560
14. Roessler S, Jia HL, Budhu A, Forgues M, Ye QH, et al. (2010) A unique metastasis gene signature enables prediction of tumor relapse in early-stage hepatocellular carcinoma patients. Cancer Res 70: 10202-10212. doi: 10.1158/0008-5472.CAN-10-2607 PMID: 21159642
15. Dancik GM, Theodorescu D (2014) Robust prognostic gene expression signatures in bladder cancer and lung adenocarcinoma depend on cell cycle related genes. PLoS One 9: e85249. doi: 10.1371/journal.pone.0085249 PMID: 24465512
16. Bao ZS, Li MY, Wang JY, Zhang CB, Wang HJ, et al. (2014) Prognostic value of a nine-gene signature in glioma patients based on mRNA expression profiling. CNS Neurosci Ther 20: 112-118. doi: 10.1111/cns.12171 PMID: 24279471
17. Armananzas R, Alonso-Nanclares L, Defelipe-Oroquieta J, Kastanauskaite A, de Sola RG, et al. (2013) Machine learning approach for the outcome prediction of temporal lobe epilepsy surgery. PLoS One 8: e62819. doi: 10.1371/journal.pone.0062819 PMID: 23646148
18. Shi M, Beauchamp RD, Zhang B (2012) A network-based gene expression signature informs prognosis and treatment for colorectal cancer patients. PLoS One 7: e41292. doi: 10.1371/journal.pone.0041292 PMID: 22844451
19. Tsuchiya M, Parker JS, Kono H, Matsuda M, Fujii H, Rusyn I (2010) Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma. Mol Cancer 9: 74. doi: 10.1186/1476-4598-9-74 PMID: 20380719
20. Okada Y, Wu D, Trynka G, Raj T, Terao C, et al. (2014) Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506: 376-381. doi: 10.1038/nature12873 PMID: 24390342
21. Sanseau P, Agarwal P, Barnes MR, Pastinen T, Richards JB, et al. (2012) Use of genome-wide association studies for drug repositioning. Nat Biotechnol 30: 317-320. doi: 10.1038/nbt.2151 PMID: 22491277
22. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121. PMID: 11309499
23. Bair E, Tibshirani R (2004) Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol 2: E108. PMID: 15094809
24. Cox DR (1972) Regression models and life tables. JR stat soc B 34: 187-220.
25. Freeman LC (1977) A set of measures of centrality based on betweenness. Sociometry: 35-41.
26. Barrat A, Barthelemy M, Pastor-Satorras R, Vespignani A (2004) The architecture of complex weighted networks. Proc Natl Acad Sci U S A 101: 3747-3752. PMID: 15007165
27. Raman K (2010) Construction and analysis of protein-protein interaction networks. Autom Exp 2: 2. doi: 10.1186/1759-4499-2-2 PMID: 20334628
28. Hwang S, Son SW, Kim SC, Kim YJ, Jeong H, Lee D (2008) A protein interaction network associated with asthma. J Theor Biol 252: 722-731. doi: 10.1016/j.jtbi.2008.02.011 PMID: 18395227
29. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research 13: 2498-2504. PMID: 14597658
30. Assenov Y, Ramírez F, Schelhorn S-E, Lengauer T, Albrecht M (2008) Computing topological parameters of biological networks. Bioinformatics 24: 282-284. PMID: 18006545
31. Kohavi R. (1995) A study of cross-validation and bootstrap for accuracy estimation and model selection; 1995. pp. 1137-1145.
32. Ward JH Jr (1963) Hierarchical grouping to optimize an objective function. Journal of the American statistical association 58: 236-244.
33. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, et al. (2010) Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29: 1093-1102. doi: 10.1038/onc.2009.416 PMID: 19946335
34. Zhu F, Shi Z, Qin C, Tao L, Liu X, et al. (2012) Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res 40: D1128-1136. doi: 10.1093/nar/gkr797 PMID: 21948793
35. Knox C, Law V, Jewison T, Liu P, Ly S, et al. (2011) DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 39: D1035-1041. doi: 10.1093/nar/gkq1126 PMID: 21059682
36. Zeng L, Yu J, Huang T, Jia H, Dong Q, et al. (2012) Differential combinatorial regulatory network analysis related to venous metastasis of hepatocellular carcinoma. BMC Genomics 13 Suppl 8: S14. doi: 10.1186/1471-2164-13-S8-S14 PMID: 23282077
37. Wei L, Lian B, Zhang Y, Li W, Gu J, et al. (2014) Application of microRNA and mRNA expression profiling on prognostic biomarker discovery for hepatocellular carcinoma. BMC Genomics 15 Suppl 1: S13. doi: 10.1186/1471-2164-15-S1-S13 PMID: 24564407
38. Tsuchiya N, Narita S, Inoue T, Saito M, Numakura K, et al. (2013) Insulin-like growth factor-1 genotypes and haplotypes influence the survival of prostate cancer patients with bone metastasis at initial diagnosis. BMC Cancer 13: 150. doi: 10.1186/1471-2407-13-150 PMID: 23530598
39. Cho EJ, Lee JH, Yoo JJ, Choi WM, Lee MJ, et al. (2013) Serum insulin-like growth factor-I level is an independent predictor of recurrence and survival in early hepatocellular carcinoma: a prospective cohort study. Clin Cancer Res 19: 4218-4227. doi: 10.1158/1078-0432.CCR-12-3443 PMID: 23757355
40. Lee JS, Chu IS, Heo J, Calvisi DF, Sun Z, et al. (2004) Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40: 667-676. PMID: 15349906
41. Toshima T, Shirabe K, Matsumoto Y, Yoshiya S, Ikegami T, et al. (2013) Autophagy enhances hepatocellular carcinoma progression by activation of mitochondrial beta-oxidation. J Gastroenterol.
42. Yu J, Shen B, Chu ES, Teoh N, Cheung KF, et al. (2010) Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro. Hepatology 51: 2008-2019. doi: 10.1002/hep.23550 PMID: 20512989
43. Schaefer KL, Wada K, Takahashi H, Matsuhashi N, Ohnishi S, et al. (2005) Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res 65: 2251-2259. PMID: 15781638
44. Berasain C, Ujue Latasa M, Urtasun R, Goni S, Elizalde M, et al. (2011) Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer. Cancers (Basel) 3: 2444-2461. doi: 10.3390/cancers3022444 PMID: 24212818
45. Schimanski CC, Bahre R, Gockel I, Muller A, Frerichs K, et al. (2006) Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4. Br J Cancer 95: 210-217. PMID: 16819541
46. Liu H, Pan Z, Li A, Fu S, Lei Y, et al. (2008) Roles of chemokine receptor 4 (CXCR4) and chemokine ligand 12 (CXCL12) in metastasis of hepatocellular carcinoma cells. Cell Mol Immunol 5: 373-378. doi: 10.1038/cmi.2008.46 PMID: 18954561
47. Shao RX, Hoshida Y, Otsuka M, Kato N, Tateishi R, et al. (2005) Hepatic gene expression profiles associated with fibrosis progression and hepatocarcinogenesis in hepatitis C patients. World J Gastroenterol 11: 1995-1999. PMID: 15800993
48. Zhang Y, Qiu Z, Wei L, Tang R, Lian B, et al. (2014) Integrated analysis of mutation data from various sources identifies key genes and signaling pathways in hepatocellular carcinoma. PLoS One 9: e100854. doi: 10.1371/journal.pone.0100854 PMID: 24988079
49. Gruden G, Setti G, Hayward A, Sugden D, Duggan S, et al. (2005) Mechanical stretch induces monocyte chemoattractant activity via an NF-kappaB-dependent monocyte chemoattractant protein-1-mediated pathway in human mesangial cells: inhibition by rosiglitazone. J Am Soc Nephrol 16: 688-696. PMID: 15677312
50. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, et al. (2004) Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 89: 2728-2735. PMID: 15181049
51. Gout PW, Buckley AR, Simms CR, Bruchovsky N (2001) Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia 15: 1633-1640. PMID: 11587223
52. Doxsee DW, Gout PW, Kurita T, Lo M, Buckley AR, et al. (2007) Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy. Prostate 67: 162-171. PMID: 17075799
53. Funao K, Matsuyama M, Kawahito Y, Sano H, Chargui J, et al. (2008) Telmisartan is a potent target for prevention and treatment in human prostate cancer. Oncol Rep 20: 295-300. PMID: 18636189
54. Martinez-Balibrea E, Abad A, Martinez-Cardus A, Gines A, Valladares M, et al. (2010) UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. Br J Cancer 103: 581-589. doi: 10.1038/sj.bjc.6605776 PMID: 20628391
55. Yu MC, Yuan JM, Lu SC (2008) Alcohol, cofactors and the genetics of hepatocellular carcinoma. J Gastroenterol Hepatol 23 Suppl 1: S92-97. doi: 10.1111/j.1440-1746.2007.05293.x PMID: 18336674
56. Yuan JM, Lu SC, Van Den Berg D, Govindarajan S, Zhang ZQ, et al. (2007) Genetic polymorphisms in the methylenetetrahydrofolate reductase and thymidylate synthase genes and risk of hepatocellular carcinoma. Hepatology 46: 749-758. PMID: 17659576
57. Louafi S, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, et al. (2007) Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 109: 1384-1390. PMID: 17330837